← Back to Home

Clear “Aged” Stem Cells Before Gene Therapy? Sickle Cell Disease Research Identifies a New Approach

Hematopoietic stem cells from young patients already show oxidative stress, DNA damage, and cellular senescence; removing damaged cells restored blood formation in models, but whether this can improve human stem cell collection and gene therapy remains to be answered by clinical trials.

By SURL BioNews

Gene therapies for sickle cell disease have curative potential, but their starting point may not be ideal: treatment first requires obtaining enough functional, high-quality hematopoietic stem cells from patients before genetic modification and reinfusion. New research from St. Jude Children’s Research Hospital indicates that even in very young patients, this critical starting material may already have sustained damage resembling premature aging.

The research team examined hematopoietic stem and progenitor cells from patients aged 6 to 23 and found features including prolonged cell cycles, elevated reactive oxygen species, DNA damage, and cellular senescence. Ex vivo testing also showed that these cells had poorer blood-forming potential. The researchers hypothesize that chronic anemia forces the bone marrow to continuously accelerate red blood cell production and that, together with hemolysis and systemic inflammation, this may deplete the stem cells’ long-term function.

The team then transplanted patient cells into mice to test whether “senolytic drugs” could remove cells that had lost function but had not undergone natural apoptosis. After treatment, senescence markers declined, and blood-forming capacity recovered to levels approaching those of the non-sickle cell disease control group. Earlier mouse experiments also showed that navitoclax could restore bone marrow stem cells capable of engraftment, providing preliminary proof of concept for this strategy.

The researchers also reproduced the improvement using a combination of dasatinib and quercetin. These two compounds have often been used together in senescent-cell research, but the current findings still come from cell and transplantation models and cannot be used to infer that patients would also benefit after taking the drugs. The appropriate dose, timing of administration, effects on normal hematopoietic cells, and long-term safety all remain unanswered clinically.

The most direct translational direction for this finding may not be to use senescent-cell clearance as a standalone therapy, but to schedule it before stem cell mobilization and collection. If the number and quality of collectable cells can be improved, this could theoretically reduce repeated collection procedures and provide healthier starting material for gene editing and autologous transplantation. St. Jude has filed a patent application covering the use of senolytic drugs to improve hematopoietic stem cell quality, collection, and transplantation in sickle cell disease, but the patent covers a proposed use and does not mean efficacy has been demonstrated.

The research has also not yet shown that this strategy can reduce the risk of blood cancers after gene therapy or directly improve patients’ pain, anemia, and organ complications. The next step will require prospective human trials to determine which cells should be cleared, when to intervene during treatment, and whether the treated stem cells can stably rebuild blood formation over the long term. Until then, it is more appropriately viewed as an experimental pathway for improving the gene therapy process rather than an anti-aging treatment ready for immediate use.

References

  1. St. Jude Children's Research Hospital
  2. PubMed
  3. WIPO patent publication via Google Patents
  4. Medical Xpress